Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Knightscope, Inc. (KSCP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Knightscope, Inc. (KSCP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Knightscope, Inc. (KSCP) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook

Analysts Estimate Deere (DE) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Deere (DE) to Report a Decline in Earnings: What to Look Out for

The market expects Deere (DE) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended April 2025. This widely-known consensus outlook is

Globant (GLOB) Earnings Expected to Grow: Should You Buy?
Globant (GLOB) Earnings Expected to Grow: Should You Buy?

Wall Street expects a year-over-year increase in earnings on higher revenues when Globant (GLOB) reports results for the quarter ended March 2025. While this widely-known consensus outlook is

Flexible Solutions International Inc. (FSI) Earnings Expected to Grow: Should You Buy?
Flexible Solutions International Inc. (FSI) Earnings Expected to Grow: Should You Buy?

The market expects Flexible Solutions International Inc. (FSI) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This

Gambling.com Group Limited (GAMB) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Gambling.com Group Limited (GAMB) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

The market expects Gambling.com Group Limited (GAMB) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known

Cava Group (CAVA) Earnings Expected to Grow: Should You Buy?
Cava Group (CAVA) Earnings Expected to Grow: Should You Buy?

Wall Street expects a year-over-year increase in earnings on higher revenues when Cava Group (CAVA) reports results for the quarter ended March 2025. While this widely-known consensus outlook is

Compared to Estimates, Olaplex (OLPX) Q1 Earnings: A Look at Key Metrics
Compared to Estimates, Olaplex (OLPX) Q1 Earnings: A Look at Key Metrics

Olaplex Holdings, Inc. (OLPX) reported $96.98 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 2%. EPS of $0.00 for the same period compares to $0.03 a

Altice USA (ATUS) Reports Q1 Earnings: What Key Metrics Have to Say
Altice USA (ATUS) Reports Q1 Earnings: What Key Metrics Have to Say

Altice USA, Inc. (ATUS) reported $2.15 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 4.4%. EPS of -$0.16 for the same period compares to -$0.05 a year

Compared to Estimates, Match Group (MTCH) Q1 Earnings: A Look at Key Metrics
Compared to Estimates, Match Group (MTCH) Q1 Earnings: A Look at Key Metrics

For the quarter ended March 2025, Match Group (MTCH) reported revenue of $831.18 million, down 3.3% over the same period last year. EPS came in at $0.67, compared to $0.44 in the year-ago quarter.

Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say
Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say

For the quarter ended March 2025, Zai Lab Limited Unsponsored ADR (ZLAB) reported revenue of $106.49 million, up 22.2% over the same period last year. EPS came in at -$0.45, compared to -$0.55 in

BCE (BCE) Reports Q1 Earnings: What Key Metrics Have to Say
BCE (BCE) Reports Q1 Earnings: What Key Metrics Have to Say

BCE (BCE) reported $4.13 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 7.4%. EPS of $0.48 for the same period compares to $0.53 a year ago.

The

Cogent (CCOI) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Cogent (CCOI) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Cogent Communications (CCOI) reported $247.05 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 7.2%. EPS of -$1.09 for the same period compares to -$1.29

Mogo Inc (MOGO) Reports Q1 Loss, Tops Revenue Estimates
Mogo Inc (MOGO) Reports Q1 Loss, Tops Revenue Estimates

Mogo Inc (MOGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.12 per share a year ago. These figures are

Best Momentum Stocks to Buy for May 8th
Best Momentum Stocks to Buy for May 8th

Here are two stocks with buy rank and strong momentum characteristics for investors to consider today, May 8th:

BrightSpring Health Services, Inc. BTSG: This home and community-based healthcare

Wall Street Analysts Believe Barrick Gold (GOLD) Could Rally 25.72%: Here's is How to Trade
Wall Street Analysts Believe Barrick Gold (GOLD) Could Rally 25.72%: Here's is How to Trade

Shares of Barrick Gold (GOLD) have gained 3.2% over the past four weeks to close the last trading session at $19.40, but there could still be a solid upside left in the stock if short-term price

Wall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a Bet
Wall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a Bet

Shares of Rigel Pharmaceuticals (RIGL) have gained 7% over the past four weeks to close the last trading session at $18.47, but there could still be a solid upside left in the stock if short-term

Wall Street Analysts Believe Unity Software (U) Could Rally 27.69%: Here's is How to Trade
Wall Street Analysts Believe Unity Software (U) Could Rally 27.69%: Here's is How to Trade

Shares of Unity Software Inc. (U) have gained 3.4% over the past four weeks to close the last trading session at $20.66, but there could still be a solid upside left in the stock if short-term price

Wall Street Analysts Think Si-Bone (SIBN) Could Surge 41.21%: Read This Before Placing a Bet
Wall Street Analysts Think Si-Bone (SIBN) Could Surge 41.21%: Read This Before Placing a Bet

Shares of Si-Bone (SIBN) have gained 25.5% over the past four weeks to close the last trading session at $17.47, but there could still be a solid upside left in the stock if short-term price targets

Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade
Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade

Shares of Immunome, Inc. (IMNM) have gained 19.7% over the past four weeks to close the last trading session at $7.43, but there could still be a solid upside left in the stock if short-term price

Can Pfizer (PFE) Climb 25.14% to Reach the Level Wall Street Analysts Expect?
Can Pfizer (PFE) Climb 25.14% to Reach the Level Wall Street Analysts Expect?

Pfizer (PFE) closed the last trading session at $22.79, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street

Wall Street Analysts See a 32.29% Upside in Adeia (ADEA): Can the Stock Really Move This High?
Wall Street Analysts See a 32.29% Upside in Adeia (ADEA): Can the Stock Really Move This High?

Shares of Adeia (ADEA) have gained 4.4% over the past four weeks to close the last trading session at $13.10, but there could still be a solid upside left in the stock if short-term price targets of

Wall Street Analysts Predict a 25.24% Upside in Clearway Energy (CWEN): Here's  What You Should Know
Wall Street Analysts Predict a 25.24% Upside in Clearway Energy (CWEN): Here's What You Should Know

Clearway Energy (CWEN) closed the last trading session at $28.61, gaining 2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall

Does Novo Nordisk (NVO) Have the Potential to Rally 51.24% as Wall Street Analysts Expect?
Does Novo Nordisk (NVO) Have the Potential to Rally 51.24% as Wall Street Analysts Expect?

Novo Nordisk (NVO) closed the last trading session at $67.55, gaining 3.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall

Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect?
Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect?

Shares of Adaptive Biotechnologies (ADPT) have gained 5.1% over the past four weeks to close the last trading session at $8.81, but there could still be a solid upside left in the stock if

Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect?
Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect?

BioCryst Pharmaceuticals (BCRX) closed the last trading session at $10.08, gaining 48.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets